Can Health Issues Affect Enclomiphene and Mounjaro?

Can Health Issues Affect Enclomiphene and Mounjaro?

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Already a member? Sign In

Timeline

00:00

A 55-year-old man asks whether his health problems could affect his response to enclomiphene and contribute to stalled weight loss on Mounjaro. His history includes type 2 diabetes, hypertension, BPH, gout, obesity, and a 70-pound weight loss, while recent labs show high total testosterone along with elevated estrogen and sex hormone-binding globulin.

01:56

Dr. O’Connor identifies significant cardiometabolic disease and reviews the man’s response to enclomiphene. Although total testosterone looks strong on paper, he points to free testosterone, elevated estrogen, excess weight, and the need to consider the broader clinical picture.

03:13

Dr. O’Connor explains how selective estrogen receptor modulators such as enclomiphene can stimulate testosterone while preserving testicular function and fertility. He questions whether fertility preservation remains necessary at age 55 and introduces why testosterone therapy may eventually be considered instead.

04:52

The focus shifts from laboratory testosterone levels to how the man actually feels, including sex drive, muscle development, and energy. Dr. O’Connor compares enclomiphene, clomiphene, and hCG with testosterone injections and discusses the role of fertility when choosing an approach.

05:55

Dr. O’Connor considers whether elevated estrogen could possibly contribute to the man’s stalled Mounjaro weight loss. He then emphasizes the ABCDs™, including A1C, blood pressure, cholesterol, and cardiovascular evaluation with calcium scoring or coronary CT angiography with plaque analysis.

07:38

The discussion returns to elevated estrogen while using enclomiphene and whether testosterone may be a better long-term approach. Dr. O’Connor considers fertility, continued weight loss, testosterone injections, and the importance of individualized medical management.

10:00

Dr. O’Connor explains how body fat and aromatization can affect estrogen and describes how enclomiphene stimulates natural testosterone production through LH and FSH. He then raises the concern that this response may diminish over time through downregulation.

11:47

Dr. O’Connor discusses his long-term clinical experience with men using clomiphene and enclomiphene and the limited evidence surrounding prolonged use. He describes a patient whose response weakened over several years, requiring progressively higher doses before eventually transitioning to testosterone.

Video Summary

Strong testosterone numbers can hide bigger questions about enclomiphene, estrogen, weight loss, and overall health. Dr. O’Connor addresses a 55-year-old man with type 2 diabetes, hypertension, BPH, gout, obesity, and other cardiometabolic concerns who has lost 70 pounds on Mounjaro. After 90 days on enclomiphene, his total testosterone is 973, but his free testosterone is less impressive and his estrogen and sex hormone-binding globulin are elevated.

Dr. O’Connor explains that enclomiphene is a selective estrogen receptor modulator that stimulates the body’s own testosterone production while helping preserve testicular function and fertility. He questions whether preserving fertility remains an important treatment goal for this man and discusses why testosterone therapy may eventually be considered instead. He also emphasizes that laboratory testosterone levels alone do not show whether treatment is improving sex drive, muscle development, energy, or overall well-being.

The discussion then turns to the man’s stalled weight loss after a year on Mounjaro. Dr. O’Connor considers whether elevated estrogen could possibly be contributing while encouraging him to continue his weight-loss efforts. Because of his cardiometabolic disease, Dr. O’Connor broadens the discussion to the ABCDs™, including A1C, blood pressure, cholesterol, and cardiovascular imaging such as a calcium score or coronary CT angiography with plaque analysis.

Dr. O’Connor returns to the choice between enclomiphene and testosterone and discusses how continued fat loss may reduce aromatization. He explains that enclomiphene blocks estrogen receptors in the brain, leading to increased LH and FSH and stimulation of the testes to produce testosterone. He also describes clinical experience suggesting that the response to clomiphene or enclomiphene may diminish over time, sometimes leading to escalating doses.

A long-term patient example illustrates this concern. Dr. O’Connor describes a man whose clomiphene and enclomiphene treatment initially produced favorable laboratory results but eventually required progressively higher doses before he transitioned to testosterone. The case reinforces Dr. O’Connor’s emphasis on individualized treatment, symptoms, cardiometabolic health, laboratory monitoring, and long-term reassessment rather than relying on testosterone numbers alone.

Drug Callouts

Enclomiphene

Enclomiphene is a selective estrogen receptor modulator discussed as a way to stimulate endogenous testosterone production while preserving testicular function and fertility. Dr. O’Connor reviews the man’s elevated testosterone and estrogen levels and discusses concerns about whether the response to enclomiphene can diminish over time.

Mounjaro (Tirzepatide)

Mounjaro, or tirzepatide, is being used for weight loss and has helped the man lose 70 pounds. His weight loss has recently stalled, leading to discussion of whether hormonal and health factors may be contributing and the importance of continuing his weight-loss efforts.

Testosterone

Testosterone therapy is discussed as an alternative to continuing enclomiphene, particularly when preserving fertility is no longer a priority. Dr. O’Connor compares direct testosterone treatment with stimulating endogenous production and discusses symptoms, estrogen, weight loss, and long-term monitoring.

Clomiphene

Clomiphene is discussed alongside enclomiphene as a selective estrogen receptor modulator used to stimulate endogenous testosterone production. Dr. O’Connor describes clinical experience in which some men required progressively higher doses as their response diminished over time.

hCG

hCG is mentioned as another approach for increasing testosterone while maintaining testicular function and fertility. Dr. O’Connor includes it when comparing fertility-preserving strategies with direct testosterone therapy.

Testosterone Cypionate

Testosterone cypionate injections are discussed as a possible alternative to enclomiphene in the theoretical case presented. Dr. O’Connor describes a conservative injectable testosterone approach while emphasizing that the discussion is educational rather than individualized medical advice.

Aromatase Inhibitors

An aromatase inhibitor is proposed by the man’s doctor because his estrogen is elevated while taking enclomiphene. Dr. O’Connor discusses the concern but is cautious about simply adding an AI and instead examines the broader hormone treatment strategy.

Condition Callouts

Type 2 Diabetes

Type 2 diabetes is part of the man’s existing cardiometabolic disease and is being medically controlled. Dr. O’Connor includes diabetes in his broader assessment of cardiovascular risk and emphasizes monitoring A1C through the ABCDs™.

Hypertension

Hypertension is one of the man’s existing controlled medical conditions and contributes to his cardiometabolic risk profile. Dr. O’Connor emphasizes blood pressure as a central component of the ABCDs™ and overall long-term health monitoring.

Obesity

Obesity remains an important concern despite the man losing 70 pounds with Mounjaro. Dr. O’Connor encourages continued weight loss and discusses how becoming leaner may reduce aromatization and influence estrogen levels.

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia is included among the man’s existing medical conditions and is reported as controlled with medication. It forms part of the broader health history Dr. O’Connor considers when reviewing the case.

Gout

Gout is another existing medical condition reported by the man and is described as controlled with medication. It contributes to the overall medical history considered during Dr. O’Connor’s review of his hormone and metabolic health.

Dyslipidemia

Dyslipidemia is identified by Dr. O’Connor as part of the man’s cardiometabolic disease. He emphasizes cholesterol management through the ABCDs™ and connects lipid health with the need for broader cardiovascular risk assessment.

Key Takeaways

A strong total testosterone level on enclomiphene does not by itself show whether treatment is producing the desired clinical results.
Elevated estrogen, free testosterone, symptoms, fertility goals, and overall health should be considered alongside total testosterone levels.
Dr. O’Connor considers elevated estrogen as one possible factor when evaluating stalled weight loss during Mounjaro treatment.
Type 2 diabetes, hypertension, dyslipidemia, and obesity make broader cardiometabolic and cardiovascular monitoring especially important.
Continued fat loss may reduce aromatization and can be an important part of managing testosterone and estrogen.
Dr. O’Connor’s clinical experience suggests that the response to clomiphene or enclomiphene can diminish over time in some men.